NASDAQ:CAI Caris Life Sciences (CAI) Stock Price, News & Analysis $16.72 +0.05 (+0.30%) Closing price 04:00 PM EasternExtended Trading$16.78 +0.06 (+0.36%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Caris Life Sciences Stock (NASDAQ:CAI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Caris Life Sciences alerts:Sign Up Key Stats Today's Range$16.58▼$17.0850-Day Range$14.55▼$21.2452-Week Range$14.19▼$42.50Volume2.19 million shsAverage Volume3.15 million shsMarket Capitalization$4.73 billionP/E RatioN/ADividend YieldN/APrice Target$27.56Consensus RatingModerate Buy Company Overview Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology. Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis. In addition to clinical testing for patient care, the company offers translational science and clinical trial support services to biopharmaceutical partners, including biomarker discovery, assay development and companion diagnostic collaborations to facilitate drug development programs. The company primarily serves healthcare providers, cancer centers and biopharma customers in the United States and through international collaborations. Its offerings are used across the oncology care continuum—from initial profiling to inform therapy selection through longitudinal monitoring and research applications—positioning the business at the intersection of clinical diagnostics and precision oncology research. Caris emphasizes the integration of multi‑omic data and computational analysis to generate clinically actionable insights, and it engages with clinicians, researchers and industry partners to expand the use of molecular profiling in personalized cancer care. Detailed information about its leadership and corporate history is available through the company’s public filings and corporate disclosures. AI Generated. May Contain Errors. Read More Caris Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks95th Percentile Overall ScoreCAI MarketRank™: Caris Life Sciences scored higher than 95% of companies evaluated by MarketBeat, and ranked 2nd out of 61 stocks in the services sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingCaris Life Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 6 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialCaris Life Sciences has a consensus price target of $27.56, representing about 64.8% upside from its current price of $16.72.Amount of Analyst CoverageCaris Life Sciences has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Caris Life Sciences' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth270.00% Earnings GrowthEarnings for Caris Life Sciences are expected to grow by 270.00% in the coming year, from $0.10 to $0.37 per share.Price to Book Value per Share RatioCaris Life Sciences has a P/B Ratio of 7.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.51% of the float of Caris Life Sciences has been sold short.Short Interest Ratio / Days to CoverCaris Life Sciences has a short interest ratio ("days to cover") of 3.18, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Caris Life Sciences has recently decreased by 7.69%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCaris Life Sciences does not currently pay a dividend.Dividend GrowthCaris Life Sciences does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.68 News SentimentCaris Life Sciences has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Services companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Caris Life Sciences this week, compared to 4 articles on an average week.Search Interest15 people have searched for CAI on MarketBeat in the last 30 days. This is an increase of 1,400% compared to the previous 30 days.MarketBeat Follows3 people have added Caris Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership3.1 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $501,457.00 in company stock, which represents 0.0106% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Caris Life Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $501,457.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders7.80% of the stock of Caris Life Sciences is held by insiders.Percentage Held by InstitutionsCaris Life Sciences has minimal institutional ownership at this time.Read more about Caris Life Sciences' insider trading history. Receive CAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Caris Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CAI Stock News HeadlinesCaris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic TestingMay 26 at 8:30 AM | prnewswire.comComparing Lumexa Imaging (NASDAQ:LMRI) & Caris Life Sciences (NASDAQ:CAI)May 25, 2026 | americanbankingnews.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.May 29 at 1:00 AM | Banyan Hill Publishing (Ad)You’ve likely never heard of Caris Life Sciences stock. Billionaire Stanley Druckenmiller has – and he likes what he sees.May 21, 2026 | msn.comCaris Life Sciences, Inc. (NASDAQ:CAI) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 21, 2026 | americanbankingnews.comAnalyzing Caris Life Sciences (NASDAQ:CAI) and CBA Florida (OTCMKTS:CBAI)May 21, 2026 | americanbankingnews.comHead to Head Contrast: Sonida Senior Living (NYSE:SNDA) and Caris Life Sciences (NASDAQ:CAI)May 20, 2026 | americanbankingnews.comCaris Life Sciences (NASDAQ:CAI) Director Jeff Vacirca Purchases 31,050 SharesMay 13, 2026 | insidertrades.comSee More Headlines CAI Stock Analysis - Frequently Asked Questions How have CAI shares performed this year? Caris Life Sciences' stock was trading at $26.98 on January 1st, 2026. Since then, CAI shares have decreased by 38.0% and is now trading at $16.72. How were Caris Life Sciences' earnings last quarter? Caris Life Sciences, Inc. (NASDAQ:CAI) posted its quarterly earnings results on Thursday, February, 26th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.01 by $0.27. Caris Life Sciences's quarterly revenue was up 125.4% on a year-over-year basis. Read the conference call transcript. When did Caris Life Sciences IPO? Caris Life Sciences (CAI) raised $459 million in an IPO on Wednesday, June 18th 2025. The company issued 23,529,412 shares at a price of $19.00-$20.00 per share. Who are Caris Life Sciences' major shareholders? Top institutional shareholders of Caris Life Sciences include Orbimed Advisors LLC (0.99%), Sei Investments Co. (0.21%), Rock Springs Capital Management LP (0.20%) and Bank of America Corp DE (0.19%). Insiders that own company stock include Luke Thomas Power and Jeff L Vacirca. View institutional ownership trends. How do I buy shares of Caris Life Sciences? Shares of CAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings2/26/2026Today5/29/2026Goldman Sachs 47th Annual Global Healthcare Conference 20266/08/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorServices Industry Services – Health Sub-IndustryHealthcare Current SymbolNASDAQ:CAI CIK2019410 WebN/A Phone(866) 771-8946FaxN/AEmployees1,846Year Founded2008Price Target and Rating Average Price Target for Caris Life Sciences$27.56 High Price Target$38.00 Low Price Target$21.00 Potential Upside/Downside+64.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($7.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$68.09 million Net Margins3.75% Pretax Margin3.73% Return on Equity98.28% Return on Assets48.87% Debt Debt-to-Equity Ratio0.64 Current Ratio7.05 Quick Ratio6.52 Sales & Book Value Annual Sales$812.03 million Price / Sales5.82 Cash Flow$1.60 per share Price / Cash Flow10.46 Book Value$2.10 per share Price / Book7.96Miscellaneous Outstanding Shares282,680,000Free Float260,632,000Market Cap$4.73 billion OptionableN/A BetaN/A Social Links The 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:CAI) was last updated on 5/29/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Caris Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Caris Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
